8-K: Syndax Revuforj Gains Second FDA Approval for AML

Syndax Pharmaceuticals announced FDA approval of Revuforj (revumenib) for relapsed or refractory acute myeloid leukemia with an NPM1 mutation in adult and pediatric patients.

Summary

• The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options.
• This marks the second FDA approval for Revuforj, following its 2024 approval for R/R acute leukemia with a KMT2A translocation.
• Revuforj is now the first and only FDA-approved therapy for both R/R AML with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation.
• The expanded approval is based on efficacy data from the Phase 2 portion of the pivotal AUGMENT-101 trial, which showed a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23% (15/65 patients; 95% CI: 14%, 35%).
• The median time to CR or CRh response was 2.8 months, and the median duration of CR or CRh was 4.5 months.
• Revumenib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for AML as a category 2A recommended treatment option for R/R NPM1m AML on September 18, 2025.
• NPM1 gene mutations are the most common genetic alteration in AML, occurring in approximately 30% of adults with AML, and are associated with high rates of relapse and poor prognosis for R/R patients.

Sentiment

Score: 8

Explanation: The FDA approval for a second indication significantly expands the market for Revuforj, solidifies Syndax's leadership in menin inhibition, and addresses a critical unmet medical need. While there are notable safety concerns, these are common with cancer therapies and are clearly outlined with management strategies. The overall impact is highly positive for the company's commercial prospects and pipeline validation.

Positives

• Secured a second FDA indication for Revuforj, significantly expanding its market and patient population.
• Revuforj is now the first and only menin inhibitor FDA-approved for multiple acute leukemia subtypes in both adults and children.
• Solidifies Syndax's leadership in menin inhibition, a new therapeutic class.
• Included in NCCN Clinical Practice Guidelines for R/R NPM1m AML as a Category 2A recommended treatment option, indicating strong clinical validation.
• Addresses a critical unmet medical need for patients with R/R NPM1m AML, an aggressive blood cancer with poor prognosis.
• Physicians already have strong familiarity with Revuforj due to its prior approval and nearly one year of commercial use, which should aid in the launch for this new indication.
• Syndax has established SyndAccess, a comprehensive program offering personalized support and financial assistance to eligible U.S. patients prescribed Revuforj.

Negatives

• Differentiation syndrome occurred in 25% of patients treated with Revuforj, with 12% being Grade 3 or 4, and was fatal in 2 patients.
• QTc interval prolongation was reported as an adverse reaction in 36% of patients, with 15% being Grade 3 and 2% Grade 4; QTcF was greater than 500 msec in 10% of patients.
• Fatal adverse reactions occurred in 9 (4%) patients, including 4 with sudden death, 2 with differentiation syndrome, 2 with hemorrhage, and 1 with cardiac arrest.
• Serious adverse reactions were reported in 184 (76%) patients, with the most frequent being infection (29%), febrile neutropenia (20%), bacterial infection (15%), differentiation syndrome (13%), and hemorrhage (11%).
• Revuforj can cause fetal harm when administered to a pregnant woman and may impair fertility based on animal findings.

Risks

• **Differentiation Syndrome**: Revuforj can cause fatal or life-threatening differentiation syndrome (DS), which occurred in 25% of patients (12% Grade 3 or 4, 2 fatal). Management requires immediate corticosteroid therapy and hemodynamic monitoring.
• **QTc Interval Prolongation and Torsades de Pointes**: Revuforj can cause QTc interval prolongation (36% of patients, 15% Grade 3, 2% Grade 4) and Torsades de Pointes. This requires careful ECG monitoring, correction of electrolyte abnormalities, and potential dose interruption or discontinuation.
• **Embryo-Fetal Toxicity**: Revuforj can cause fetal harm. Females of reproductive potential and males with female partners must use effective contraception during treatment and for 4 months after the last dose.
• **Infertility**: Based on animal findings, Revuforj may impair fertility, though the effects were reversible.
• **Drug Interactions**: Concomitant use with strong CYP3A4 inhibitors requires dose reduction, while strong or moderate CYP3A4 inducers should be avoided. Concomitant use with QTc-prolonging drugs should also be avoided or managed with increased ECG monitoring.
• **Pediatric Patients**: Requires monitoring of bone growth and development.
• **Forward-Looking Statements**: Actual results may differ materially from expectations due to unexpected safety or efficacy data, lower-than-expected clinical trial enrollment, changes in competition or the regulatory environment, failure of collaborators, and unexpected litigation or disputes.

Future Outlook

Syndax Pharmaceuticals plans to make Revuforj commercially available for patients with R/R AML with a susceptible NPM1 mutation. The company intends to continue innovating for patients with menin-dependent acute leukemias and aims to lead the development of this therapeutic class into the frontline. Multiple trials of revumenib are ongoing or planned across the treatment landscape, including in combination with standard of care therapies in newly diagnosed patients with NPM1m or KMT2Ar AML.

Management Comments

• "We are thrilled to have secured a second indication for Revuforj, making it the first and only menin inhibitor that is FDA-approved for multiple acute leukemia subtypes in both adults and children." Michael A. Metzger, Chief Executive Officer.
• "The breadth of the indicated patient population highlights the compelling and consistent efficacy and tolerability of Revuforj in multiple different types of patients." Michael A. Metzger, Chief Executive Officer.
• "Our launch into this second population will greatly benefit from physicians already strong familiarity with Revuforj and positive experience treating well over 1,000 patients in clinical trials and nearly one year of commercial use." Michael A. Metzger, Chief Executive Officer.
• "We will continue to innovate for patients with menin-dependent acute leukemias and look forward to leading the development of this exciting new therapeutic class into the frontline." Michael A. Metzger, Chief Executive Officer.
• "The expanded FDA approval of Revuforj marks a major advancement in the management of acute leukemia patients. For the first time, a targeted, oral therapy that is well tolerated and efficacious is approved for R/R NPM1 mutated AML and R/R KMT2A translocated acute leukemia." Joshua F. Zeidner, M.D., Chief, Leukemia Research at the University of North Carolina, Lineberger Comprehensive Cancer Center.
• "The compelling clinical activity observed with Revuforj in clinical trials and clinical practice paves the way for a new standard of care for these two aggressive and difficult-to-treat blood cancers." Joshua F. Zeidner, M.D.
• "The FDA approval of a precision treatment that selectively targets the pathway driving this form of AML offers new hope to patients and their loved ones." Lore Gruenbaum, Ph.D., Chief Scientific Officer of Blood Cancer United.

Industry Context

This FDA approval positions Revuforj as a significant advancement in the treatment of acute leukemias, particularly for relapsed or refractory NPM1 mutated AML and KMT2A translocated acute leukemia, which are aggressive and difficult-to-treat blood cancers. The drug's status as the first and only menin inhibitor approved for multiple acute leukemia subtypes in both adults and children establishes Syndax as a leader in this therapeutic class. Its inclusion in NCCN Clinical Practice Guidelines further validates its importance in clinical practice, potentially shifting the standard of care for these patient populations and addressing a critical unmet medical need.

Comparison to Industry Standards

• Revuforj is the first and only FDA-approved therapy for both R/R AML with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation, distinguishing it from other available treatments.
• The approval of a targeted, oral therapy for these specific R/R acute leukemias represents a new standard of care, as highlighted by Joshua F. Zeidner, M.D., Chief, Leukemia Research at the University of North Carolina, Lineberger Comprehensive Cancer Center.
• The NCCN Guidelines' Category 2A recommendation for R/R NPM1m AML places Revuforj among established and effective treatment options, indicating strong clinical evidence and acceptance within the oncology community.

Stakeholder Impact

• **Shareholders**: Positive impact due to expanded market, increased revenue potential, and validation of the company's drug pipeline.
• **Patients (Adult and Pediatric)**: Significant positive impact by providing a new, targeted, and efficacious treatment option for R/R AML with NPM1 mutation, addressing a critical unmet medical need.
• **Clinicians**: Provides a new standard of care and a well-tolerated, targeted oral therapy for difficult-to-treat acute leukemias, supported by NCCN Guidelines.
• **Employees**: Positive impact on morale and job security due to company success and market expansion.

Next Steps

• Syndax plans to make Revuforj commercially available for patients with R/R AML with a susceptible NPM1 mutation.
• Syndax will continue to innovate for patients with menin-dependent acute leukemias.
• Syndax looks forward to leading the development of this new therapeutic class into the frontline.
• Multiple trials of revumenib are ongoing or planned across the treatment landscape, including in combination with standard of care therapies in newly diagnosed patients with NPM1m or KMT2Ar AML.

Key Dates

Recommendation

The FDA approval of Revuforj for a second, significant indication in R/R NPM1 mutated AML is a major positive catalyst. This expands the addressable patient population, reinforces Syndax's leadership in the menin inhibitor class, and provides a new standard of care for a difficult-to-treat cancer. The inclusion in NCCN guidelines further supports adoption. While safety concerns exist, they are typical for oncology drugs and are managed. This approval significantly enhances the company's commercial prospects and validates its pipeline, making it a strong buy for long-term growth.

Keywords

Syndax Pharmaceuticals, SNDX, FDA Approval, Revuforj, revumenib, Acute Myeloid Leukemia, AML, NPM1 mutation, Relapsed Refractory, R/R AML, Menin Inhibitor, Oncology, Cancer Therapy, Biopharmaceutical, KMT2A translocation, AUGMENT-101, NCCN Guidelines